{"id":5446,"date":"2026-01-08T11:33:24","date_gmt":"2026-01-08T08:33:24","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5446"},"modified":"2026-01-08T11:33:26","modified_gmt":"2026-01-08T08:33:26","slug":"nxera-pharma-exclusive-licensing-agreement-agamree-vamorolone-santhera-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/nxera-pharma-exclusive-licensing-agreement-agamree-vamorolone-santhera-pharmaceuticals\/","title":{"rendered":"Nxera Pharma, Santhera Pharmaceuticals'tan Duchenne Musk\u00fcler Distrofi i\u00e7in Vamorolone'nun Japonya ve Belirli Asya-Pasifik Haklar\u0131n\u0131n Lisans\u0131n\u0131 Ald\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Nxera Pharma (\u201cNxera\u201d veya \u201c\u015eirket; TSE 4565\u201c), Duchenne Musk\u00fcler Distrofisi (DMD) tedavisi i\u00e7in vamorolonun geli\u015ftirilmesi, \u00fcretimi ve ticarile\u015ftirilmesi konusunda Japonya, G\u00fcney Kore, Avustralya ve Yeni Zelanda&#039;da Santhera Pharmaceuticals Holding (\u201dSanthera\u201d) ile m\u00fcnhas\u0131r bir lisans anla\u015fmas\u0131 imzalad\u0131\u011f\u0131n\u0131 duyuruyor. Vamorolone, nadir g\u00f6r\u00fclen kal\u0131tsal bir n\u00f6rodejeneratif hastal\u0131k olan DMD&#039;nin tedavisi i\u00e7in ABD, Avrupa Birli\u011fi, \u0130ngiltere ve \u00c7in&#039;de AGAMREE olarak onaylanm\u0131\u015f ve pazarlanmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-agamree-vamorolone-what-is-agamree-used-for\/\" target=\"_blank\" rel=\"noreferrer noopener\">Agamree (vamorolone) Nedir? Agamree Ne \u0130\u00e7in Kullan\u0131l\u0131r?<\/a><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vamorolone, ABD, Avrupa Birli\u011fi, \u0130ngiltere ve \u00c7in&#039;de Duchenne Musk\u00fcler Distrofisi (DMD) tedavisi i\u00e7in AGAMREE ad\u0131yla onaylanm\u0131\u015f ve pazarlanmaktad\u0131r.<\/strong><\/li>\n\n\n\n<li>Vamorolon ile ilgili yeni be\u015f y\u0131ll\u0131k veriler, omurga k\u0131r\u0131klar\u0131nda azalma, katarakt insidans\u0131nda d\u00fc\u015f\u00fc\u015f ve normal b\u00fcy\u00fcme h\u0131z\u0131n\u0131n korunmas\u0131yla birlikte \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirilmi\u015f bir g\u00fcvenlik profilini ortaya koymu\u015ftur. Yan etkilerin geleneksel kortikosteroid tedavisinin temel s\u0131n\u0131rlamalar\u0131ndan biri oldu\u011fu g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, vamorolonun g\u00fcvenlik profili ve kar\u015f\u0131la\u015ft\u0131r\u0131labilir etkinli\u011fi, mevcut steroid tedavilerinin yerini alma potansiyeline sahiptir.<\/li>\n\n\n\n<li><strong>Bu i\u015flem, Nxera&#039;n\u0131n 2030 vizyonu do\u011frultusunda Japonya\/APAC b\u00f6lgesindeki hastalara yenilik\u00e7i ila\u00e7lar sunma misyonunu ve y\u00fcksek b\u00fcy\u00fcme oran\u0131na sahip, y\u00fcksek karl\u0131 bir Japon biyofarmas\u00f6tik \u015firketi kurma hedefini ilerletmektedir.<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nxera Pharma (\u201cNxera\u201d or \u201cthe Company; TSE 4565) announces that it has entered an exclusive licensing agreement for the development, manufacturing and commercialization of vamorolone for the treatment of Duchenne Muscular Dystrophy (DMD) in Japan, South Korea, Australia and New Zealand with Santhera Pharmaceuticals Holding (\u201cSanthera\u201d) Vamorolone is approved and marketed as AGAMREE for the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5447,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,142,474,41,43],"class_list":["post-5446","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-japan","tag-nxera-pharma","tag-santhera","tag-vamorolone"],"subtitle":"Santhera, AGAMREE (Vamorolone)'yi Nxera Pharma'ya Japonya, G\u00fcney Kore, Avustralya ve Yeni Zelanda'da 205 milyon ABD dolar\u0131na kadar varan bir telif \u00fccreti kar\u015f\u0131l\u0131\u011f\u0131nda lisanslad\u0131.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5446"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5446\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5447"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}